Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (131-140 of 322) with videos related to

Pageof 33
Sort By:
Oncotarget|October 10, 2015
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemiaHouda Alachkar, Martin Mutonga, Gregory Malnassy, et al.
Pediatric Blood & Cancer|March 2, 2012
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology GroupMatthew A Kutny, Barry K Moser, Kristina Laumann, et al.
Experimental Hematology & Oncology|January 10, 2019
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplantYun Fan, Andrew S Artz, Koen van Besien, et al.
Blood Neoplasia|May 7, 2026
Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemiaIan J Saldanha, Yuliia Sereda, Ghid Kanaan, et al.
Haematologica|May 13, 2014
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipientsLori S Muffly, Masha Kocherginsky, Wendy Stock, et al.
Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantationAndrew S Artz, Daniel A Pollyea, Masha Kocherginsky, et al.
Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for InterventionAndrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
American Journal of Hematology|April 21, 2020
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemiaSonia Christian, Saad Arain, Pritesh Patel, et al.
Pageof 33

Showing results (131-140 of 322) with videos related to

Sort By:
Pageof 33
Oncotarget|October 10, 2015
T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemiaHouda Alachkar, Martin Mutonga, Gregory Malnassy, et al.
Pediatric Blood & Cancer|March 2, 2012
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology GroupMatthew A Kutny, Barry K Moser, Kristina Laumann, et al.
Experimental Hematology & Oncology|January 10, 2019
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplantYun Fan, Andrew S Artz, Koen van Besien, et al.
Blood Neoplasia|May 7, 2026
Prioritized health outcomes for adolescents and young adults with acute lymphoblastic leukemiaIan J Saldanha, Yuliia Sereda, Ghid Kanaan, et al.
Haematologica|May 13, 2014
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipientsLori S Muffly, Masha Kocherginsky, Wendy Stock, et al.
Cancer|March 29, 2019
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantationAndrew S Artz, Daniel A Pollyea, Masha Kocherginsky, et al.
Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2022
Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for InterventionAndrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
American Journal of Hematology|April 21, 2020
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemiaSonia Christian, Saad Arain, Pritesh Patel, et al.
Pageof 33